Inhibrx Biosciences (INBX) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Inhibrx Biosciences (INBX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | - | - | - | 1.30M | - | 100K | - | 100K | - | 1.65M (+1275.00%) | 120K (+300.00%) | 30K | - |
Operating Expenses | |||||||||||||
Research And Development | 25M (-0.51%) | 25M (-11.18%) | 29M (+28.15%) | 22M (-39.61%) | 37M (+10.52%) | 33M (-14.19%) | 39M (-42.50%) | 68M (+5.92%) | 64M (-46.56%) | 119M (+213.93%) | 38M (+11.58%) | 34M | - |
Selling General And Administrative | 5.71M (+2.51%) | 5.57M (+5.49%) | 5.28M (-17.76%) | 6.42M (+6.64%) | 6.02M (-63.87%) | 17M (+110.89%) | 7.90M (-91.54%) | 93M (+836.51%) | 9.97M (-29.94%) | 14M (+80.35%) | 7.89M (+8.68%) | 7.26M | - |
Operating Expenses | 31M (+0.03%) | 31M (-8.55%) | 34M (+17.85%) | 29M (-33.12%) | 43M (-14.25%) | 50M (+6.90%) | 47M (-70.93%) | 161M (+118.07%) | 74M (-44.78%) | 134M (+190.99%) | 46M (+11.07%) | 41M | - |
Depreciation And Amortization | 540K (-3.57%) | 560K (-3.45%) | 580K (-12.12%) | 660K (-2.94%) | 680K (-1.45%) | 690K (-9.21%) | 760K (+58.33%) | 480K (+33.33%) | 360K (-38.98%) | 590K (+96.67%) | 300K (0.00%) | 300K | - |
Operating Income | |||||||||||||
Operating Income | -30.93M (+0.03%) | -30.92M (-8.55%) | -33.81M (+23.44%) | -27.39M (-36.15%) | -42.90M (-14.08%) | -49.93M (+6.69%) | -46.80M (-70.91%) | -160.90M (+117.96%) | -73.82M (-44.10%) | -132.05M (+188.13%) | -45.83M (+10.86%) | -41.34M | - |
Ebit | -30.93M (+0.03%) | -30.92M (-8.55%) | -33.81M (+23.44%) | -27.39M (-36.15%) | -42.90M (-14.08%) | -49.93M (+6.69%) | -46.80M (-70.91%) | -160.90M (+117.96%) | -73.82M (-11.21%) | -83.14M (+81.41%) | -45.83M (+10.86%) | -41.34M (-15.49%) | -48.92M |
EBITDA | -30.39M (+0.10%) | -30.36M (-8.64%) | -33.23M (+24.32%) | -26.73M (-36.70%) | -42.23M (-14.24%) | -49.24M (+6.95%) | -46.04M (-71.30%) | -160.42M (+118.38%) | -73.46M (-11.01%) | -82.55M (+81.35%) | -45.52M (+10.92%) | -41.04M (-16.11%) | -48.92M |
Other Income / Expenses | |||||||||||||
Interest Expense | 3.51M (+10.03%) | 3.19M (+0.31%) | 3.18M (+1.27%) | 3.14M (+16.73%) | 2.69M | - | - | 5.36M (-34.07%) | 8.13M (-48.51%) | 16M (+93.74%) | 8.15M (+3.03%) | 7.91M | - |
Other Non Operating Income | -10.00K (-97.37%) | -380.00K (+660.00%) | -50.00K (-80.00%) | -250.00K (+400.00%) | -50.00K | 80K (+100.00%) | 40K (+33.33%) | 30K | -60.00K (-89.66%) | -580.00K (+346.15%) | -130.00K (-40.91%) | -220.00K | - |
Net Income | |||||||||||||
Income Before Tax | -33.44M (+1.86%) | -32.83M (-6.89%) | -35.26M (+23.07%) | -28.65M (-33.85%) | -43.31M (-9.51%) | -47.86M (+9.12%) | -43.86M | 1.86B | -78.71M | 99M | -51.79M (+10.07%) | -47.05M | - |
Income Tax Expense | - | - | - | - | - | - | - | - | - | - | - | 10K | - |
Net Income From Continuing Operations | -33.44M (+1.86%) | -32.83M (-6.89%) | -35.26M (+23.07%) | -28.65M (-33.85%) | -43.31M (-9.51%) | -47.86M (+9.12%) | -43.86M | 1.86B | -78.71M (-15.91%) | -93.60M (+80.73%) | -51.79M (+10.07%) | -47.05M (-3.82%) | -48.92M |
Net Income | -33.44M (+1.86%) | -32.83M (-6.89%) | -35.26M (+23.07%) | -28.65M (-33.85%) | -43.31M (-9.51%) | -47.86M (+9.12%) | -43.86M | 1.86B | -78.71M (-15.91%) | -93.60M (+80.73%) | -51.79M (+10.07%) | -47.05M (-3.82%) | -48.92M |